BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28740577)

  • 1. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.
    Mehner C; Oberg AL; Goergen KM; Kalli KR; Maurer MJ; Nassar A; Goode EL; Keeney GL; Jatoi A; Radisky DC; Radisky ES
    Genes Cancer; 2017 May; 8(5-6):589-599. PubMed ID: 28740577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.
    Cohen D; Lane B; Jin T; Magi-Galluzzi C; Finke J; Rini BI; Bukowski RM; Zhou M
    Clin Genitourin Cancer; 2007 Mar; 5(4):264-70. PubMed ID: 17553206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of EGF receptor expression in early glottic cancer.
    Demiral AN; Sarioglu S; Birlik B; Sen M; Kinay M
    Auris Nasus Larynx; 2004 Dec; 31(4):417-24. PubMed ID: 15571917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
    Jung M; Lee C; Park JH; Moon KC
    Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
    Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
    Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
    Lee CM; Lee RJ; Hammond E; Tsodikov A; Dodson M; Zempolich K; Gaffney DK
    Gynecol Oncol; 2004 Apr; 93(1):209-14. PubMed ID: 15047238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.
    Psyrri A; Kassar M; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8637-43. PubMed ID: 16361548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours.
    Higgins PA; Brady A; Dobbs SP; Salto-Tellez M; Maxwell P; McCluggage WG
    Histopathology; 2014 Apr; 64(5):633-8. PubMed ID: 24206174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.
    Higaki E; Kuwata T; Nagatsuma AK; Nishida Y; Kinoshita T; Aizawa M; Nitta H; Nagino M; Ochiai A
    Gastric Cancer; 2016 Jan; 19(1):63-73. PubMed ID: 25487305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome.
    Yan G; Saeed MEM; Foersch S; Schneider J; Roth W; Efferth T
    Oncotarget; 2019 Mar; 10(20):1918-1931. PubMed ID: 30956774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases.
    Chaux A; Munari E; Katz B; Sharma R; Lecksell K; Cubilla AL; Burnett AL; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2690-5. PubMed ID: 24075601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP
    Petersen I; Dietel M; Geilenkeuser WJ; Mireskandari M; Weichert W; Steiger K; Scheel AH; Büttner R; Schirmacher P; Warth A; Lasitschka F; Schildhaus HU; Kirchner T; Reu S; Kreipe H; Länger F; Tiemann M; Schulte C; Jöhrens K
    Pathol Res Pract; 2017 Dec; 213(12):1530-1535. PubMed ID: 29108919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
    Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
    Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.
    Psyrri A; Yu Z; Weinberger PM; Sasaki C; Haffty B; Camp R; Rimm D; Burtness BA
    Clin Cancer Res; 2005 Aug; 11(16):5856-62. PubMed ID: 16115926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
    Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
    Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.
    Bhargava R; Chen B; Klimstra DS; Saltz LB; Hedvat C; Tang LH; Gerald W; Teruya-Feldstein J; Paty PB; Qin J; Shia J
    Cancer; 2006 Apr; 106(8):1857-62. PubMed ID: 16532444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.